Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCM.0000000000001334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NMR-based structural integrity analysis of therapeutic monoclonal antibodies: a comparative study of Humira and its biosimilars.
MAbs
December 2025
Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
The analytical comparability of biologic products and their biosimilars, including higher-order structure (HOS) assessment, ensures product quality and is required for regulatory approval. In this study, nuclear magnetic resonance (NMR) spectroscopy was used to evaluate the HOS of Humira (adalimumab) and its biosimilars under normal and photo-stressed conditions. Under normal conditions, 1D and 2D NMR spectra showed strong structural similarity among all products.
View Article and Find Full Text PDFEarly Changes in House Dust Mite Component Specific Immunoglobulin Levels Predict the One-Year Efficacy of Allergen Immunotherapy in Patients With Allergic Rhinitis.
Clin Transl Allergy
September 2025
Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Background: The efficacy of subcutaneous immunotherapy (SCIT) in allergic rhinitis (AR) patients varies. Component-resolved diagnostics (CRD) may serve as a useful tool to predict therapeutic responses.
Methods: Forty-three house dust mite (HDM)-sensitized AR patients undergoing SCIT were enrolled.
Utility of Breath-Holding Time in Monitoring Acute Neuromuscular Respiratory Failure in Bulbar-Onset Myasthenia Gravis: A Case Report.
Cureus
August 2025
Respiratory Medicine, Birmingham Heartlands Hospital (Part of University Hospitals Birmingham NHS Trust), Birmingham, GBR.
We report the management of a 64-year-old male with newly diagnosed bulbar-onset myasthenia gravis (MG) who was hospitalized with acute neuromuscular respiratory insufficiency. This case highlights the challenges in monitoring respiratory function in MG patients, especially in the presence of bulbar and nuchal weakness, and emphasizes the potential utility of single breath-hold time (SBHT) over forced vital capacity (FVC) as a reliable bedside monitoring tool. Despite initial stabilization with intravenous immunoglobulin (IVIG), the patient deteriorated, requiring escalation to the intensive care unit (ICU), and the clinical worsening corresponded with the SBHT rather than with FVC.
View Article and Find Full Text PDFTranscriptomic activation of immune cell trafficking predicts antidepressant response to minocycline.
J Affect Disord
September 2025
King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, SE5 9RT, UK; National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College Lond
Although inflammation has been suggested as a promising therapeutic target for major depressive disorder (MDD), uncertainty remains about how to recognise individuals who may benefit from anti-inflammatory treatments. Transcriptomic profiles provide an important tool to identify relevant biological mechanisms associated with response. In this study, we investigate: i) the ability of transcriptomic profiles to predict antidepressant response to anti-inflammatory treatment with minocycline, and ii) the effect of minocycline on transcriptomic profiles based on the antidepressant response.
View Article and Find Full Text PDFNovel Radiofluorinated Nanobody PET Tracer for Preclinical Studies of TIM3 Expression.
Mol Pharm
September 2025
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Departmen
T-cell immunoglobulin and mucin domain-3 (TIM3) is an inhibitory checkpoint glycoprotein expressed on immune cells, particularly tumor-infiltrating lymphocytes (TILs), and plays a critical role in suppressing antitumor immune responses. While dual blockade of TIM3 and programmed cell death protein 1 (PD1) has shown promising results in enhancing immune responses in advanced cancers, the lack of reliable, noninvasive methods for detecting TIM3 expression in tumors remains a major challenge. To address this, we developed and characterized a novel positron emission tomography (PET) tracer, [F]AlF-RESCA-HVCR2N2, based on a TIM3-specific nanobody labeled via [F]AlF radiochemistry.
View Article and Find Full Text PDF